Condition: Ovarian Carcinoma · Fallopian Tube Carcinoma · Primary Peritoneal Carcinoma · Sponsor: Peking University Cancer Hospital & Institute
The purpose of this study is to evaluate the efficacy, safety, and quality of life scores of patients with HER2-expressing platinum-sensitive recurrent epithelial ovarian cancer treated with the combination therapy regimen of RC48 plus platinum with or without bevacizumab.
This description comes directly from the study's public registry record.
Hong Zheng, M.D. · 86-010-88196100 · zhhong306@hotmail.com
Always discuss trial participation with your own doctor first.
| Hong Zheng | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06420973